Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer
Michail Athanasopoulos , Pinelopi Samara , Georgios Agrogiannis , Ioannis Athanasopoulos , Nikolaos Kavantzas , Efthymios Kyrodimos , Nicholas S. Mastronikolis
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002292
Laryngeal cancer, a subtype of head and neck cancer, poses significant challenges due to its profound impact on essential functions such as speech and swallowing and poor survival rates in advanced stages. Traditional treatments-surgery, radiotherapy, and chemotherapy-are often associated with high morbidity and substantial recurrence rates, emphasizing the urgent need for novel therapeutic approaches. Immune checkpoint inhibitors (ICIs) have revolutionized oncology by countering tumor-induced immune evasion, restoring immune surveillance, and activating T-cell responses against cancer. This review examines the role of ICIs in laryngeal cancer management, with a focus on pembrolizumab and nivolumab (anti-PD-1 agents), which are clinically established, as well as investigational therapies such as dostarlimab (anti-PD-1), atezolizumab (anti-PD-L1), and ipilimumab (anti-CTLA-4). Pembrolizumab, in combination with platinum-based chemotherapy and 5-fluorouracil, is approved as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), based on evidence from the Keynote-048 trial. This pivotal trial demonstrated significant overall survival (OS) benefits over the cetuximab-based standard regimen. Similarly, nivolumab showed improved OS in the CheckMate-141 trial, supporting its approval as a second-line therapy for patients with platinum-refractory disease. ICIs have shown durable survival benefits and a more manageable toxicity profile compared to traditional chemotherapy. Immune-related adverse events are generally mild and controllable; however, in some cases, they can become severe and even life-threatening. Furthermore, ICIs are being investigated in combination with radiotherapy, as well as in neoadjuvant and adjuvant settings, where preliminary findings suggest these approaches may enhance efficacy, preserve organ function, and overcome resistance to conventional treatments. The integration of ICIs into multimodal treatment strategies holds promise for transforming the therapeutic landscape of advanced laryngeal cancer. This review synthesizes current evidence, highlights ongoing research, and explores strategies to enhance survival and quality of life for patients facing this challenging malignancy.
Laryngeal cancer / immune checkpoint inhibitors / nivolumab / pembrolizumab / PD-1/PD-L1 / CTLA-4 / clinical trials / immune-related adverse events
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
Ferlito A, Silver CE, Zeitels SM, Rinaldo A. Evolution of laryngeal cancer surgery. Acta Otolaryngol. 2002; 122: 665-72. |
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Pembrolizumab (KEYTRUDA) [Internet]. US Food and Drug Administration; [cited 2025 Jan 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda |
| [10] |
Nivolumab for SCCHN [Internet]. US Food and Drug Administration; [cited 2025 Jan 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn |
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
Karpathiou G, |
| [24] |
|
| [25] |
|
| [26] |
Clinicaltrials.gov [Internet]. Bethesda: National Library of Medicine; [cited 2025 Jan 15]. Available from: https://clinicaltrials.gov/ |
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
Burtness B, |
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
Dougan M. Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. Cancer Immunol Res. 2020; 8: 1230-5. |
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
Runnels J, Bloom JR, Hsieh K, Dickstein DR, Shi Y, Jones BM, |
| [56] |
|
| [57] |
|
/
| 〈 |
|
〉 |